IFITM3 and fungal infectious disease: Interestingly, we found that AmphoB, an anti-mycotic drug commonly used for systemic fungal infections [62,63], could dramatically enhanced the cell entry of SARS-CoVs and SL-CoVs (Figure 6(A)), and completely blocked IFITM3-mediated restriction, but did not affect IFITM1-mediated restriction (Figure 6(C)).